These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31727874)

  • 1. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
    Robinson AM; Rathore R; Redlich NJ; Adkins DR; VanArsdale T; Van Tine BA; Michel LS
    Cell Death Dis; 2019 Nov; 10(11):867. PubMed ID: 31727874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
    Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
    Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC.
    Goto Y; Koshizuka K; Ando T; Izumi H; Wu X; Sato K; Ishikawa T; Ford K; Feng X; Wang Z; Arang N; Allevato MM; Kishore A; Mali P; Gutkind JS
    Cancer Res Commun; 2024 Jul; 4(7):1850-1862. PubMed ID: 38954773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
    Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
    BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATR inhibition sensitizes HPV
    Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
    Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma.
    Adkins D; Ley J; Cohen J; Oppelt P
    Cancer J; 2022 Sep-Oct 01; 28(5):377-380. PubMed ID: 36165726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Ngamphaiboon N; Pattaranutaporn P; Lukerak S; Siripoon T; Jinawath A; Arsa L; Shantavasinkul PC; Taonam N; Trachu N; Jinawath N; Kositwattanarerk A; Sananmuang T; Jiarpinitnun C
    Clin Cancer Res; 2024 Jan; 30(2):294-303. PubMed ID: 37982827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo.
    Li R; Wang Q; Zhao Y; Zhu Y; Wang X
    Mol Biol Rep; 2024 Mar; 51(1):455. PubMed ID: 38536540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas.
    Göttgens EL; Bussink J; Leszczynska KB; Peters H; Span PN; Hammond EM
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):548-558. PubMed ID: 31271827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Michel L; Ley J; Wildes TM; Schaffer A; Robinson A; Chun SE; Lee W; Lewis J; Trinkaus K; Adkins D
    Oral Oncol; 2016 Jul; 58():41-8. PubMed ID: 27311401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
    De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
    Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
    Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax.
    Gadsden NJ; Fulcher CD; Li D; Shrivastava N; Thomas C; Segall JE; Prystowsky MB; Schlecht NF; Gavathiotis E; Ow TJ
    Mol Cancer Res; 2021 May; 19(5):862-873. PubMed ID: 33495400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
    van Caloen G; Machiels JP
    Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumour effects of metformin and curcumin in human papillomavirus positive and negative head and neck cancer cells.
    Lindsay C; Kostiuk M; Conrad D; O'Connell DA; Harris J; Seikaly H; Biron VL
    Mol Carcinog; 2019 Nov; 58(11):1946-1959. PubMed ID: 31338907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Gene Expression Profiling of Tobacco-Associated HPV-Positive versus Negative Oral Squamous Carcinoma Cell Lines.
    Lepore S; Lettini G; Condelli V; Sisinni L; Piscazzi A; Simeon V; Zoppoli P; Pedicillo MC; Natalicchio MI; Pietrafesa M; Landriscina M
    Int J Med Sci; 2020; 17(1):112-124. PubMed ID: 31929745
    [No Abstract]   [Full Text] [Related]  

  • 18. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
    Leonard B; Brand TM; O'Keefe RA; Lee ED; Zeng Y; Kemmer JD; Li H; Grandis JR; Bhola NE
    Cancer Res; 2018 Aug; 78(15):4331-4343. PubMed ID: 29792310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK4/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas.
    Duah E; Seligson ND; Persaud AK; Dam Q; Pabla N; Rocco JW; Li J; Poi M
    Mol Carcinog; 2023 Aug; 62(8):1201-1212. PubMed ID: 37132760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
    Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
    Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.